Roche
NEWS
This morning, Genentech released results of its Phase III IMpower 133 trial that showed treatment with Tecentriq plus chemotherapy helped people with extensive-stage small cell lung cancer live significantly longer than with chemotherapy alone.
AstraZeneca and its MedImmune division released data on overall survival (OS) in its Phase III PACIFIC clinical trial of Imfinzi (durvalumab).
The two biggest areas for biotech startups in the U.S. are Cambridge in Boston and the San Francisco Bay Area. They’re also the locations of astonishingly expensive real estate. But they’re where biotechs seem to want to be because they’re close to talent, academic research institutions, and the attention of venture capital.
The Economist Intelligence Unit (EIU) has carried out two complementary studies on lung cancer in Latin America: an analysis of the economic costs and an assessment of the policy response (the Latin America Lung Cancer Traffic Lights).
Novo Nordisk is laying off 400 staffers so it can shift funds toward biological and technological innovation.
Days after a report by The New York Times and ProPublica revealed José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center, failed to disclose his vast financial ties to various companies in journal articles, the noted cancer researcher has resigned from his position.
Last year’s influenza season in the U.S. had record-breaking hospitalization rates. A lot of industry observers are looking at a new flu drug, baloxavir marboxil, for which clinical trial data was just published.
Oncolytics Biotech® Inc. today announced that it has entered into a Master Clinical Supply Agreement (Agreement) with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq®) for use in the company’s clinical development program.
José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center came under fire this weekend for his failure to disclose financial ties to various pharmaceutical companies when he published research papers in peer-reviewed journals.
JOBS
IN THE PRESS